{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:56Z","timestamp":1786993496320,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtha.2024.07.007","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T20:03:39Z","timestamp":1721073819000},"page":"2713-2723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration"],"prefix":"10.1016","volume":"22","author":[{"given":"Kathrin","family":"Sch\u00f6n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Pestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Riedesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waltraud","family":"Seyfert-Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Claar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Rezvani-Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-8796","authenticated-orcid":false,"given":"Padmapriya","family":"Ponnuswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc W.","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.07.007_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.32607\/20758251-2012-4-2-62-73","article-title":"Coagulation factor IX for hemophilia B therapy","volume":"4","author":"Orlova","year":"2012","journal-title":"Acta Naturae"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2024.07.007_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2516.2006.01263.x","article-title":"Genetic diagnosis of haemophilia and other inherited bleeding disorders","volume":"12","author":"Peyvandi","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.007_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1586\/17474086.1.1.87","article-title":"Update on the physiology and pathology of factor IX activation by factor XIa","volume":"1","author":"Smith","year":"2008","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.07.007_bib4","unstructured":"Konkle BA, Nakaya Fletcher S. Hemophilia B. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews\u00ae, Seattle: University of Washington; 1993\u20132023."},{"key":"10.1016\/j.jtha.2024.07.007_bib5","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1517\/14656566.6.9.1517","article-title":"Christmas disease","volume":"6","author":"Giangrande","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jtha.2024.07.007_bib6","first-page":"27","article-title":"New developments in the management of moderate-to-severe hemophilia B","volume":"7","author":"Nazeef","year":"2016","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2024.07.007_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2516.2001.00465.x","article-title":"Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis","volume":"7","author":"Bj\u00f6rkman","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.007_bib8","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/j.1538-7836.2012.04826.x","article-title":"Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs","volume":"10","author":"Nolte","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.07.007_bib9","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0049-3848(09)70157-4","article-title":"Half-life extension through albumin fusion technologies","volume":"124","author":"Schulte","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.07.007_bib10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1160\/TH09-04-0255","article-title":"Genetic fusion to albumin improves the pharmacokinetic properties of factor IX","volume":"102","author":"Metzner","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.007_bib11","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1111\/hae.14036","article-title":"Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study","volume":"26","author":"Pasi","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.007_bib13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.15259","article-title":"Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients","volume":"19","author":"You","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.007_bib14","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.007_bib15","author":"Arruda"},{"key":"10.1016\/j.jtha.2024.07.007_bib16","author":"Claar"},{"key":"10.1016\/j.jtha.2024.07.007_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/jth.14332","article-title":"Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays","volume":"17","author":"Horn","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.007_bib18","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","article-title":"A\u00a0coagulation factor IX-deficient mouse model for human hemophilia B","volume":"90","author":"Lin","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.007_bib19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1055\/s-0038-1656082","article-title":"Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B","volume":"77","author":"Liles","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.007_bib20","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1055\/s-0037-1613091","article-title":"Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys","volume":"87","author":"McCarthy","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.007_bib21","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2003-05-1498","article-title":"Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs","volume":"102","author":"Russell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.007_bib22","unstructured":"Nolte MW, Hermann S, Raquet E, Kaspereit F, Krege W, Doerr B, Zollner S, Herzog E. Clinically-relevant bioavailability of rIX-FP after subcutaneous administration to rodent and non-rodent species. Poster (no. PB1114) presented at: XXVI Congress of the International Society on Thrombosis and Haemostasis (ISTH 2017); July 11, 2017. Berlin, Germany."},{"key":"10.1016\/j.jtha.2024.07.007_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240896","article-title":"Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa","volume":"15","author":"Nichols","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.07.007_bib24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/hae.14315","article-title":"Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B","volume":"27","author":"Mahlangu","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.007_bib25","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1007\/s12325-023-02570-6","article-title":"Model-informed support of dose selection for prophylactic treatment with dalcinonacog alfa in adult and paediatric hemophilia B patients","volume":"40","author":"Faraj","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtha.2024.07.007_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.07.007_bib27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.007_bib29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.007_bib30","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.07.007_bib31","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1182\/blood-2022-166135","volume":"140","author":"Pipe","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.007_bib32","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T20:53:57Z","timestamp":1739480037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624004240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1538783624004240"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.007","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}